WHENJune 21, 2014 @ 8:00am - 5:00pm

Please take our survey:  https://www.surveymonkey.com/s/8RXKNBT



[dt_sc_tab title=”Program”]

Date: June 21th, 2014, 8:00am-5:00pm
Location: Hilton, San Diego/Del Mar
Registration: Closed
$30 for early birds (by June 18th), $50 for onsite registration, students and postdocs $10 off (The fees include parking at the hotel, program brochure, continental breakfast, coffee break, and lunch). Online registration closes after June 18th.
Organizer: Sino-American Biotechnology & Pharmaceutical Professionals Association (SABPA)
Co-organizer: BayHelix, SDCAA, ACS-SD, UCSD

Bio-Pharma Conference, SABPA’s annual flagship event is fast approaching. With the recent new waves of IPOs, mergers & acquisitions, and new drug approvals, this year we will showcase many San Diego biopharma companies and research institutes that are pushing the boundaries with new breakthroughs in therapeutics ranging from small molecules, to proteins to nucleic acids and somewhere in between.  You will hear many success stories from notable companies such as Aragon. This conference will also bring together many business leaders from around the globe with renewed enthusiasm of investing in San Diego biotechnology industry to share their insights on industry trends. The program is guaranteed to generate sizzling discussions and stimulate new ideas.


8:00 am Exhibition (all day)
8:00 am Continental Breakfast & Registration
8:45 am Opening RemarksMingzhu Zhang, President, SABPA San Diego
9:00 am Keynote Speaker:David Kabakoff, Ph.D., Executive Partner, Sofinnova Ventures
9:40 am Session I. Alan Lewis, Ph.D., CEO, MedistemDale Boger, Ph.D., Chair, Department of Chemistry, Scripps Research Institute
10:40 am Coffee Break
11:00 am Session II, Panel Discussion: The Renaissance of San Diego Biopharmaceutical Industry
Moderator: Timothy Hoctor, Vice President, Professional Services, Elsevier Life Science Solutions
Chrysa Mineo, M.B.A., SVP, Receptos
Mike Grey, President and CEO, Lumena Pharmaceuticals, Inc.; Venture Partner, Pappas Ventures
Henry Ji, Ph.D., Co-Founder, CEO, Sorrento Therapeutics, Inc.
Xiaobo Wang, Ph.D., Vice President, Chief Technology Officer, ACEA Biosciences
12:00 am Luncheon
 1:30 pm San Diego Bio-Pharma Achievement Award
Award Recipient: Richard Heyman, Ph.D., President and CEO, Seragon Pharmaceuticals
 2:10 pm Session III.
Alann Paau, CLP, MBA, Ph.D., Executive Director & Vice Provost for Technology Transfer & Economic Development, Cornell University. [Slide deck]
Jonathan Wang, Ph.D., Asia Senior Managing Partner, OrbiMed
 3:10 pm Coffee Break
 3:40 pm Session IV Plenary Discussion: Innovation and Business Transactions on a Global Scale (organized by BayHelix)
Moderator: Wei-Wei Zhang, M.D., Ph.D., Managing Director, Adventin, Inc.Greg Scott, Chairman, ChinaBio® Group
Jun Ren, Ph.D., CEO, NewSummit Group
Xianping Lu, Ph.D., Chairman, CEO and CSO, Shenzhen Chipscreen Biosciences
Yajun Guo, M.D., Ph.D., Director, National Engineering Center for Antibody Medicine; Director, State Key Laboratory of Antibody Medicine and Targeting Therapy
Zhi Yang, Ph.D., Managing Partner, BioVeda China Fund
 4:30 pm Session V Presentation from Wuhan Biolake
Junjie Yang, M.D., Ph.D., Chairman and CTO, Wuhan Optic Valley Bridgebio Bio-technology Ltd
 4:45 pm Closing  and iPad-mini raffle


[dt_sc_tab title=”Speaker”]

Xian-Ping Lu, Ph.D., CEO & CSO, Chipscreen Biosciences Ltd., Shenzhen, China

Confirmed Speakers, Panelists, Chairs, and Moderators :

  • David Kabakoff, Ph.D, Executive Partner, Sofinnova Ventures and Partner, HealthQuest Ventures
  • Alan J Lewis, Ph.D., CEO, Medistem
  • Dale L. Boger, Ph.D., Professor, Department of Chemistry, The Scripps Research Institute
  • Richard A. Heyman, Ph.D., CEO of Seragon Pharmaceuticals
  • Alan Paau, CLP, MBA, Ph.D., Executive Director & Vice Provost for Technology Transfer,
    Cornell University
  • Jonathan Wang, Ph. D, Senior Managing Director, Asia at OrbiMed
  • Mr. Timothy Hoctor, Vice President, Professional Services, Elsevier Life Science Solutions
  • Chrysa Mineo, Senior Vice President, Corporate Development, Receptos
  • Mike Grey, B.S., President and CEO, Lumena Pharmaceuticals, Inc.; Venture Partner, Pappas Ventures
  • Henry Ji, Ph.D., Director, President and CEO of Sorrento Therapeutics, Inc.
  • Xiaobo Wang, Ph.D., Chief Technology Officer and Vice President, ACEA Biosciences, Inc.
  • Wei-Wei Zhang, MD, PhD., Managing Director, Adventin, Inc.
  • Yajun Guo, Ph.D., Director of SMMU Cancer Institute, Shanghai, China, Director of PLA General Hospital Cancer Center, Beijing, China, President of Chinese Engineering Research Center for Antibody Medicine, P.R. China
  • Xian-Ping Lu, Ph.D., CEO & CSO, Shenzhen Chipscreen Biosciences, Ltd.
  • Mr. Jun Ren, Founder, Chairman & CEO, Shanghai NewSummit Biopharma Group Ltd. P.R. China
  • Greg B. Scott, Founder and Chairman, ChinaBio® Group
  • Zhi Yang, Ph.D., Chairman, Managing Partner & Founder, BVCF

Session Chairs:

  • Mingzhu Zhang,, PhD, Vice President, Medicilon
  • Yi Liu, PhD, CSO, Wellspring Biosciences, Inc.
  • Jiangchun Xu, PhD, Director of Biology, Quanticel Pharmaceuticals
  • Wendy Wang, M.S., Founder and Principle Consultant, Boulder International
  • Yahu A. Liu, PhD, Research Investigator I, Genomics Institute of the Novartis Research Foundation
  • Yang Liu, Ph.D., Director of R&D, Sanford-Burnham Medical Research Institute
  • Xiangming Fang, PhD, President and Co-Founder, Denovo Biomarkers
  • Yung-Chih Wang, PhD, MBA, Vice President of Corporate Development, China, HUYA Bioscience
  • Lina Ma, Ph.D., Postdoc, Salk Institute for Biological Studies


David Kabakoff, Ph. D,  Executive Partner, Sofinnova Ventures and Partner, HealthQuest Ventures.
 KabakoffD Dr. Kabakoff joined Sofinnova Ventures in 2007. He has more than 30 years of experience in R&D and executive management roles in venture backed biotech companies. David has been Chairman, President and/or CEO of five companies that have generated over $3B in aggregate exit value on $837M in invested capital. David currently serves as Chairman of Cebix, and is a board member of Intermune (ITMN), and Allylix. He also serves as Board observer at Histogenics and Nucana. He was formerly Chairman of Trius (TSRX), from inception through its sale in 2013 to Cubist for $707 Million, and  Chairman of Amplimmune ,from inception to its sale in 2013 to Astra-Zeneca for up to $500 Million. He was formerly an active advisor and board observer to IntelliKine. Prior to joining Sofinnova, David was CEO of Salmedix, which was sold to Cephalon for $200M.  David has been active in the San Diego biotech industry since 1983 and has held senior roles at Hybritech, Corvas, Dura, and Spiros including three CEO roles leading to two IPOs and two trade sales. He has participated in raising over $1 Billion for venture backed companies and supervised over a dozen corporate partnerships.David holds a PhD in organic chemistry from Yale. He currently resides in Rancho Santa Fe with his wife, and he enjoys fine wine, travel, and skiing. [Back to top]
Alan J Lewis, Ph.D., CEO of Medistem
LewisAJ Dr. Lewis recently served as CEO at Medistem Inc, a public regenerative medicines company. He is also a Board of Director of Biomarin, Targazyme, Diavacs and HabitID.  He previously was President and CEO of Ambit Biosciences, a public biotechnology company. Dr. Lewis also served as CEO of the Juvenile Diabetes Research Foundation( JDRF) and Novocell( Viacyte), a regenerative medicines company focused on diabetes. He was President of the Signal Research Division of Celgene after Celgene acquired Signal Pharmaceuticals where he was CEO. He held a number of positions at Wyeth including VP Research.Dr Lewis received a Ph.D. in pharmacology from the University of Wales in Cardiff and completed a postdoctoral fellowship at Yale. He was awarded an Honorary Fellowship from the University of Wales in Swansea. [Back to top]
Dale L. Boger, Ph.D., Professor, Department of Chemistry, The Scripps Research Institute.
BogerDL Dr. Dale Boger received his B.Sc. in chemistry from the University of Kansas, Lawrence, Kansas (1975, with highest distinction and honors in chemistry) and Ph.D. in chemistry from Harvard University (1980) under the direction of E. J. Corey.  He returned to the University of Kansas as a member of the faculty in the Department of Medicinal Chemistry (1979-1985), moved to the Department of Chemistry at Purdue University (1985-1991), and joined the faculty in the newly created Department of Chemistry at The Scripps Research Institute (1991-present) as the Richard and Alice Cramer Professor of Chemistry. Since 2012, he has served as the Chairman for the Department of Chemistry. Professor Boger is internationally recognized for his work in organic synthesis, heterocyclic chemistry, natural products total synthesis and biological evaluation, synthetic methodology development, and medicinal chemistry, and has made seminal contributions to the understanding of DNA-drug interactions of naturally occurring antitumor-antibiotics. Dr. Bogger received numerous honors and awards including as elected member to US National Academy of Sciences. [Back to top]
Richard A. Heyman, Ph.D., CEO of Seragon Pharmaceuticals
HeymanRA Dr. Heyman, currently serves as CEO of Seragon Pharmaceuticals, a biotech company recently spun-out of Aragon Pharmaceuticals that focuses on the development of Selective Estrogen Receptor Degraders (SERDs) targeting hormone dependent cancers.  He was cofounder and CEO of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson in August 2013 for $650 million in cash upfront along with $350 million in contingent development milestones.  Previously, he cofounded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases, which was acquired by Exelixis in 2004. Prior to X-Ceptor, he held various roles at Ligand Pharmaceuticals, including Vice President of Research, where he served as project leader leading to the successful identification and development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents.  Dr. Heyman serves on the Board of Directors for BIOCOM, Organovo Inc., and The Jenna Druck Center, a non-profit in San Diego. He is also a member of the Therapeutic Advisory Board for aTyr Pharma and serves on the Executive Committee of the UCSD Moores Cancer Center.  He was an NIH postdoctoral fellow and staff scientist at the Salk Institute, working with Dr. Ronald Evans.Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut. [Back to top]
Alan Paau, CLP, MBA, Ph.D., Executive Director & Vice Provost for Technology Transfer, Cornell University
PaauA Dr. Paau currently heads the technology transfer program at Cornell University. Prior to joining Cornell in January 2007, Dr. Paau was Director and Assistant Vice Chancellor for Technology Transfer & Intellectual Property Services at UCSD for nine years. From 1994 to 1998, he was Executive Director of the Iowa State University Research Foundation, Inc. and Director of Intellectual Property & Technology Transfer at Iowa State University. Until 1994, he was Associate Director of the Biotechnology Center at the Ohio State University.Before returning to the academic environment in 1992, Dr. Paau held various research and management positions of increasing responsibilities in the Cetus Corporation and the W.R. Grace & Co. organizations for 12 years and led the development of two commercial products.Dr. Paau holds a Ph.D. degree in Biological Sciences and a Master of Business Administration degree. He also attended the Drake University School of Law. Dr. Paau has supervised the completion of over 1,600 technology license transactions with more than 140 new businesses founded from the licensing of such technologies. [Back to top]
Jonathan Wang, Ph.D., Senior Managing Director, Asia at OrbiMed
 WangJ Dr. Wang is a Senior Managing Director, Asia at OrbiMed.  With over 20 years of healthcare and life sciences experience, spanning investment, finance and research, he has co-founded OrbiMed Asia.  Previously, he was a Partner at Legend Capital and General Manager, Greater China at Burrill & Company.  He also worked for WI Harper Group, where he was a Managing Director overseeing the firm’s life sciences activities worldwide, and Walden International. He was a Board Director at ForteBio, Inc. (acquired by Pall Corporation) and is Chairman at Bonovo Orthopedics, Inc. He is a Board Director at EA, Inc. (formerly Chairman), Response Biomedical Corporation (TSE: RBM) and Waterstone Pharmaceuticals, Inc.  He is a co-founder and former Chairman of The BayHelix Group, a premier organization of Chinese life sciences business leaders.Dr. Wang holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University. [Back to top]
Mr. Timothy Hoctor, Vice President, Professional Services, Elsevier Life Science Solutions
HoctorT Mr. Hoctor has been with Elsevier Life Science group for 16 years and is responsible for the life science professional services team of scientific and semantic domain experts. The professional services consulting organization defines and oversees collaborative projects with leading global pharmaceutical companies and research groups. Prior to his current role, Tim has held a number of technical and management roles at Elsevier, responsible for development of commercial products in discovery pharmacology and chemistry informatics. Before joining Elsevier from MDL Information Systems, Tim held technical positions at Oracle and Sun Microsystems.Mr. Hoctor holds a B.S. from the University of Southern California and has completed graduate programs in technology and management from Stanford University and MIT. [Back to top]
Chrysa Mineo, Senior Vice President, Corporate Development, Receptos
 MineoC Ms. Mineo serves as Senior Vice President, Corporate Development for Receptos and is responsible for the Company’s collaborations with AbbVie, Ono, Lilly, and Janssen Pharmaceuticals. She also played a key role in the Series A and B financing for Receptos, and in the transition of Receptos from a private venture-backed company to a successful IPO candidate in 2013. Ms. Mineo has 24 years of experience in the biotechnology industry, including in roles of increasing responsibility from 1997 to 2009 leading to Senior Director of Business Development for Neurocrine Biosciences. Ms. Mineo led or played a primary role in negotiating and closing more than 28 licensing transactions, 11 of which were product candidate out-licensing deals, eight of which were in clinical development from Phase 1 to registration. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. She began her career in 1987 with Amgen as a member of a cellular biology team investigating the therapeutic role of Neupogen®.Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and received her M.B.A. from Duke University’s Fuqua School of Business. [Back to top]
Mike Grey, B.S., President and CEO, Lumena Pharmaceuticals, Inc.; Venture Partner, Pappas Ventures
 GreyM Mr. Mike Grey currently serves as president and chief executive officer at Lumena Pharmaceuticals, Inc., which recently announced that it was merging with Shire plc, and is a venture partner at Pappas Ventures. Mike has nearly 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of Auspex Pharmaceuticals, Inc., president and chief executive officer of SGX Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2008, president and chief executive officer of Trega Biosciences, Inc., which was acquired by Lion Bioscience in 2001, and president of BioChem Therapeutic Inc. For approximately 20 years, Mike served in various roles with Glaxo, Inc. and Glaxo Holdings, P.L.C., culminating in his position as vice president, corporate development and director of international licensing. Mike also serves on the board of directors of BioMarin Pharmaceutical Inc., Horizon Pharma, Inc.  and Selventa, Inc.He received a B.S. in Chemistry from the University of Nottingham in the United Kingdom. [Back to top]
Henry Ji, Ph.D.,  Director, President and CEO of Sorrento Therapeutics, Inc.
 JiH Dr. Ji co-founded and has served as a director of Sorrento Therapeutics, Inc. since January 2006, and as its CEO and President since September 2012. Dr. Ji served as Sorrento’s CSO from November 2008 to September 2012, and as its Interim CEO from April 2011 to September 2012.In 2002, Dr. Ji founded and was President of BioVintage, a biopharmaceutical company. From 2001 to 2002, Dr. Ji served as VP of CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and CEO from its founding until 1999.Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. [Back to top]
Xiaobo Wang, Ph.D., Chief Technology Officer and Vice President, ACEA Biosciences, Inc.
WangXB Dr. Wang received his B.Sc. in telecommunication and information technology from Xidian University, Xi’an, China in 1983 and conducted his Ph.D. and post-doctoral work in biophysical sensor development in University of Wales, UK between 1987 and 1992.   Dr. Wang joined University of Texas MD Anderson Cancer Center as a Research Associate in 1993 and became a faculty as an Assistant Professor in 1996.   His work mainly focused on the development of biochips and biosensors for biophysical analysis and processing of biological cells in bioMEMS and microfluidic systems.  His research work received multiple million dollars funding from US federal and state government agencies such as DARPA, NIH and Texas ATP programs.Dr. Wang joined AVIVA Biosciences as a Senior Director of R&D in 1999,  and co-founded ACEA Biosciences in 2002 and is now the Chief Technology Officer and Vice President of ACEA.   In his over 10 year’s industrial endeavor, Dr. Wang developed the break-through ion-channel chip technology for high throughput patch-clamp recording and innovative electronic sensor platform for label-free, real-time cell-based assays.   Dr. Wang has published more than 60 research papers and has over 30 issued US patents in various areas of biosensors and biochip applications. [Back to top]
Wei-Wei Zhang, M.D., Ph.D., Managing Director, Adventin, Inc.
ZhangWW Since 2006, Dr. Zhang has been pursuing translational medicine, technology transfer from US to China, and leading the projects of development and organizing enterprise investment funds to support the new venture or joint venture development in China. He has founded, co-founded, and led operations for more than eight biotechnology companies and established two corporate and academic R&D units. Some his accomplishment highlights are:

  • Invented and developed the world first Cancer Gene Therapy product (Adp53);
  • Participated in raising the $50M initial funding for Introgen Therapeutics;
  • Founded Shenzhen SiBiono GeneTech Co and raised $8 million equivalent RMB;
  • Invented and developed MiniAdFVIII in GenStar Rx, going public in AMEX, resulted in corporate value increase 100 times from $6 to $600M;
  • Invented and developed IgY Seppro®, obtained over $20 M contracts and sales;
  • Participated in developing a RMB VC/PE fund in China (total committed $300M).

Dr. Zhang was Assistant Professor in MD Anderson Cancer Center. He performed his postdoctoral research at Baylor College of Medicine. Dr. Zhang published more than 60 peer-reviewed articles and was invited present at numerous national and international bio conferences.  Dr. Zhang hold M.D. from Zhejiang Medical University in China, Ph. D. from University of Alabama. [Back to top]

Yajun Guo, Director of SMMU Cancer Institute, Shanghai; Director of PLA General Hospital Cancer Center, Beijing; President of Chinese Engineering Research Center for Antibody Medicine, P.R. China
GuoYJ Dr. Yajun Guo completed his M.D. and Ph.D from TMMU and SMMU in China and postdoctoral studies from Harvard Medical School. Dr. Yajun Guo has received many honor and awards. In 1996, Dr. Yajun Guo became a professor in Sidney Kimmel Cancer Center in San Diego and relocated his laboratory to Eppley Cancer Research Institute of Nebraska University Medical Center at Omaha in 2000. Starting from 1994, Dr. Yajun Guo established the Shanghai Tumor Immunology and Gene Therapy Center as an international research program and in 1999. He enlarged the center into the present International Joint Cancer Institute. From 2009, he has been working as a director of PLA general hospital cancer center. He is a distinguished professor and director at Shanghai International Joint Cancer Institute, PLA General Hospital Cancer Center and Chinese National Engineering Research Center for Antibody Medicine. He is also a PI of the National Key Basic Research Program Project“Structure and Function of Antibody” and is conducting Seven clinical trials of therapeutic antibodies in China. Currently, Dr. Yajun Guo has several visiting professorships in USA, UK and Australia. [Back to top]
Xian-Ping Lu, Ph.D., CEO & CSO, Shenzhen Chipscreen Biosciences, Ltd.
LuXP Dr. Lu founded Chipscreen Biosciences, the leading drug R&D company in China focusing on innovative small molecular therapeutics, 13 years ago with a group of US-trained professionals.  Previously he was Director of Research at Galderma R&D (subsidiary of L’Oreal and Nestle) in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University.  He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals.With over 20 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings.  He has published more than 60 peer-reviewed papers in prestigious journals including Nature and Science.  He is the lead inventor of over 60 patented inventions in areas of small molecule therapeutics.Dr. Lu came to the US in 1989 for postgraduate fellowship at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University. [Back to top]
Jun Ren, Founder, Chairman & CEO, Shanghai NewSummit Biopharma Group Ltd. P.R. China
RenJ In 2001, Mr. Ren founded Shanghai NewSummit Biopharma Group Co., Ltd., a new drug development process solutions provider. Mr. Ren was General Manager of Shanghai Industrial Medical University Biotechnology Co., a subsidiary of Shanghai Fosun Industrial Co., Ltd. (publicly listed). Mr. Ren has over 25 years of managerial experience in medical industry R&D, new drug registration, manufacturing and capital operation, and solid technical background in new drug R&D. He also has rich expertise in integrating resources for new drug registration, clinical trials, and industrialization. Mr. Ren has won numerous awards in China, including the Government Special Subsidy, Second Prize of National Science & Technology Advancement, First Prize of Science & Technology Achievement Award from the Ministry of Health, etc.Mr. Ren also plays key roles on the China Medical Biotechnology Association Quality Control Professionals Committee, China Medical Biotechnology Association BioProduct Professionals Committee, Shanghai Biopharmaceutical Industry Council and Shanghai Biotechnology Association, etc.Mr. Ren obtained his EMBA from CEIBS and MD from Fudan University. [Back to top]
Greg B. Scott, Founder and Chairman, ChinaBio® Group
 ScottGB Mr. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China.  ChinaBio® Consulting works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. In 2014, Greg launched ChinaBio® Ventures with Daan Gene and Foshan City to invest in companies bringing western products and technology to China. ChinaBio® Events has organized over 30 conferences focused on investment and partnering, including the highly successful ChinaBio® Partnering Forum which draws over 800 attendees from around the world to China each spring. Greg is also co-founder of two angel investment groups that have funded over 45 biotechnology and medical device companies in the U.S. and China, and Executive Editor of ChinaBio® Today, the most widely read source for China life science news.  Greg lives and works in Shanghai but visits San Diego several times a year to enjoy the blue skies and sandy beaches. [Back to top]
Zhi Yang, Ph.D., Chairman, Managing Partner & Founder, BVCF
 YangZ Dr. Yang founded BVCF in 2005. He has over 16 years of China and U.S. life sciences investment experience, with a total of over 20 years in the life sciences industry as a private equity investor, venture capital investor, senior executive, entrepreneur, and scientific inventor.  As private equity and venture capital investor, he has built portfolios of 25 companies, with 8 exits (4 IPO, 4 acquisitions). As entrepreneur, he co-founded 7 companies, 6 of which continue to conduct business and grow. As scientist, he was the principal inventor of more than 10 U.S. and international patents, which have been documented to have earned MNC’s over $250 million. He was a senior fellow and faculty member at Rockefeller University and is now an advisor to the China Health and Medical Development Foundation, under China’s Ministry of Health.Dr. Yang earned his Ph.D. in Molecular Biology and Biochemistry at Harvard University as a fellow of CUSBEA’s first class, the first group of mainland Chinese biology scholars selected to be brought to the U.S. after China opened its doors in 1979. [Back to top]
Mingzhu Zhang, Ph.D., Vice President, Medicilon
ZhangM Dr. Mingzhu Zhang is the VP of business development and head of US BD at Shanghai Medicilon, one of the leading preclinical CROs in China.  In the past 7 years, Dr. Zhang has built  strong  network  with  US  pharmaceuticals,  Chinese  pharmaceuticals  and  CROs, introduced business from more than 50 US biotech/pharmaceutical companies to Chinese CROs,  facilitated  several  licensing  deals  between US biotech  and  China  pharmaceutical companies and coordinated the collaboration.Dr. Zhang is the president of SABPA San Diego and vice chair of the board of director of SABPA (Sino-American Biomedical and Pharmaceutical Professionals Association), a non-profit organization based in San Diego.  She has served at SABPA for 7 years as chair of Fund-raising committee (2006-2010), Chair of China Connection Committee (2010-2011), executive VP of SABPA (2011-2012).  She also served as the chair of career development committee at the ACS (American Chemical Society) San Diego Section (2008-2009), and VP of  Membership  and  Sponsorship  of  ACCEF  (American  Chinese  Culture  and  Education Foundation) (2004-2006).Dr. Zhang holds a Ph.D. degree in organic chemistry from Shanghai Institute of Organic Chemistry (SIOC) and was a post-doctoral fellow in the Scripps Research Institute (TSRI) and then Vanderbilt University.  Dr. Zhang has 7 years experience in business development, 8  years  experience  in  pharmaceutical  industry  including  DuPont  Pharmaceuticals  and Neurocrine Biosciences. [Back to top]
Yi Liu, Ph.D., CSO, Wellspring Biosciences, Inc.
LiuY Dr. Liu currently serves as CSO of Wellspring Biosciences, a biotech company he co-founded that focuses on the discovery and development of small molecule drugs for the treatment of cancer.  Dr. Liu was a co-founder and Vice President of Intellikine. The company advanced three drug candidates into clinical trials in four years before it was acquired by Takeda in 2012 for a total of $310M.  Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation (GNF).  Previously, he held research roles at both SGX Pharmaceuticals and Curagen.  Dr. Liu is passionate in drug discovery and development and has a proven record of delivering high quality clinical candidates for the treatment of cancer.  He has extensive experience and leadership roles in structure-based design, cancer biology, translational research and clinical biomarker application.  He is a co-inventor of more than 40 patents and patent applications and co-author of more than 40 scientific publications.Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his M.S. in Computational Chemistry from Beijing University and his B.Eng. in Chemical Engineering from Tsinghua University. [Back to top]
Jiangchun Xu, PhD, Director of Biology, Quanticel Pharmaceuticals
XuJ Dr. JC Xu  is Director of Biology, Quanticel Pharmaceuticals. She has more than 15 years of experience in oncology drug discovery and development. Before joining Quanticel, Dr. Xu was with Pfizer for three and a half years and led the cancer genomics projects in the Pfizer Asia Disease group within the Oncology Research Unit. Prior to joining Pfizer, she was Principal Scientist of Oncology Therapeutic Area at Amgen where she led a number of cancer drug discovery programs in hematological cancers. Before joining Amgen, Dr. Xu was Group Leader at Corixa Corporation leading a number of tumor antigen discovery programs utilizing multiple cancer omics approaches. At Corixa, Dr. Xu’s team discovered P504S or AMACR, a diagnostic marker for prostate cancer that is being widely used
in clinical practice for prostate cancer diagnosis. Dr. Xu received her MD degree from Beijing Medical University, now Peking University Health Science Center and her PhD in Immunology from University of Alabama at Birmingham. She had her post-doc training at DNAX Research Institute with Dr. Kevin Moore performing research on IL-10 and IL-10R. She is an inventor of 46 issued patents and 57 pending patents and published more than 40 articles in the peer-reviewed journals.[Back to top]
Wendy Wang,, M.S., Founder and Principle Consultant, Boulder International
WangW Ms. Wendy Wang is the Sr Validation Engineer at Genoptix. Previously, Wendy worked at Pfizer as a Q&C site lead for La Jolla Site Business Technology Service. Wendy has over 15 years integrated experiences in Quality System, Regulatory Compliance (GxPs), Auditing/Vendor Management, Information Security, Project Management, Record Management, and Business Protection. Specifically, she is a Subject Matter Expert in Computer Validation and Compliance, and has been actively involved as a key author in creating V&V guidance document for IT professionals in Life Science industry. Before joining
Pfizer, she held various scientific and engineering positions in biotech company and research/engineering organizations (Agouron, University of California, Riverside, Pharmacy School of The Ohio State University, and R&D Center of Chinese Aerospace Department). Wendy holds a BS in Chemistry from Sichuan University and a MS in Chemistry from New Mexico Tech. Additionally She holds numerous professional certifications in the area of Quality, Auditing, Organization Excellence and Continuous Improvement (CQA, CSQE, CQOE, Six-Sigma).[Back to top]
Yahu A. Liu, Ph.D.,Research Investigator I, Genomics Institute of the Novartis Research Foundation
Yahu Dr. Yahu A. Liu is a research investigator at Genomics Institute of the Novartis Research Foundation, and also serves as Executive VP and a member of BOD in Sino-American Biotechnology and Pharmaceutical Professional Association (SABPA). He previously worked in medicinal chemistry teams at ChemBridge (San Diego, CA), Vertex (San Diego, CA), and Pfizer (Kalamazoo, MI). Prior to coming to the states, he had worked as an associate director in the Chinese Institute of Standards and Technology, CTO of Huarui Fine Chemical Co. Ltd. and a Certificate Engineer (Organic Process Chemistry) at WH Chemical Co. (Beijing, China). In drug discovery research, Yahu is a co-inventor of a couple of preclinical candidates (GTx-134 and 186). His main contribution to organic chemistry includes his discovery of three rearrangement reactions and synthesis of two natural products. He has been a co-editor of two books, an issue editor of two journals, a co-organizer of more than 20 conferences/symposiums and an ad hoc reviewer for 10 scientific journals. Yahu has co-authored more than 100 scientific research papers, invited reviews, granted patents, published patent applications, and US national/international meeting presentations, which have been cited for ~700 times. He received SABPA Outstanding Leadership Award in 2011, SABPA Achievement Award in 2008 and SBTSC Scientific and Technical Achievement award twice.
Yahu received his Ph.D. degree from Case Western Reserve University (Cleveland, OH) in the laboratory of the late Professor Lawrence M. Sayre (Chemistry/Pathology/Environmental Health Sciences). He earned a degree of Master of Engineering from Beijing Institute of Light Industry and obtained his early chemistry education at Shanxi Teacher’s College (China).[Back to top]
Yang Liu, Ph.D., Director of R&D, Sanford-Burnham Medical Research Institute
LiuYang Dr. Yang Liu has eight years of experience in the bioscience reagent field. In early 2003, Dr. Liu first joined Genome Biosciences, Inc, a company that provided genetic modified mouse services. Soon, the company was merged with Chemicon and Dr. Liu started to lead the New Technology Evaluation team at Chemicon, which was acquired by Serologicals in 2003 and then by Millipore in 2006. In 2008 Dr. Liu joined Stemgent, a specialized stem cell reagent company and has been the R&D director since then.Dr. Liu earned his Ph.D. in Developmental and Molecular Biology from Albert Einstein College of Medicine at New York, and had the postdoc training at University of California at San Diego. [Back to top]
Xiangming Fang, PhD, President and Co-Founder, Denovo Biomarkers
xiangming Dr. Xiangming Fang is president and co-founder of Denovo Biomarkers, a biotech startup founded in 2011, specialized in biomarker discovery and personalized medicine. Xiangming Fang has 27 years of experience in biomedical research and product development, including 21 years of biotech industry experience and 15 years of management experience. She was also involved in several startup companies with hands on experience for team building and operation. Previously as the Senior Vice President and Chief Scientific Officer at GenWay Biotech, she is responsible for new technology and product development and production, as well as customer support and partnership coordination. Prior to GenWay, Dr. Fang served at GenStar Therapeutics, initially as the Director of the Cancer Program and the Director of Preclinical Studies, then as Vice President, Hemophilia and Vector Development. Dr. Fang’s earlier experiences include gene therapy product development for hemophilia at Baxter Healthcare and GeneMedicine Inc. Dr. Fang obtained her Medical Degree at Zhejiang University Medical School and PhD in Molecular Biology at the University of Alabama. She completed her postdoctoral studies at the University of Texas, MD Anderson Cancer Center. Dr. Fang was the President (2009-2010) of SABPA, San Diego chapter, and current Chair of BOD. [Back to top]
Yung-Chih Wang, PhD, MBA, Vice President of Corporate Development, China, HUYA Bioscience
WangYC Dr. Yung-Chih Wang is VP of Corporate Development-China at HUYA Bioscience, a U.S.-headquartered company collaborating with Chinese innovators to develop novel therapeutics from China for global markets.Dr. Wang’s main responsibilities include optimal planning and execution of strategies to build HUYA’s team and collaborative networks in China for achieving the corporate goals.has over 15 years of industry experience in pharmaceutical R&D, alliance establishment and business development, plus16 years’ academic research experience in biochemistry and molecular biology. Before joining HUYA in 2010, she was Senior Scientist at Ferring Pharmaceuticals, where she led projects in drug target identification and validation, drug screening and characterization.She also established and managed collaborations with external groups, formed and implemented strategic plans for drug discovery programs, and synthesized knowledge from scientific and business data for management decision-making.Dr. Wang has been an active SABPA member since 2007 and formerly served as Chair of the Pacific Forum 2011-2013. She received her Ph.D. in Biochemistry from the University of Iowa, postdoctoral training at Cold Spring Harbor Laboratory, and MBA from the Rady School of Management at University of California, San Diego.She also received her M.S. in Biochemistry and B.Sc. in Botany from National Taiwan University. [Back to top]
Lina Ma, Ph.D, Postdoc, Salk Institute for Biological Studies
MaLN Dr. Lina Ma is a Postdoc in the Salk Institute for Biological Studies. She has been working on the genetic basis of certain respiratory disease and using integrated approach to identify the pathogenic mutations and characterize the molecular mechanism for this congenital disease. Dr. Ma has an extensive experience and broad knowledge of molecular biology, genetics, cell biology, biochemistry and bioinformatics. She has co-authored 12 publications on some top-tier journals. Dr. Ma has been active in SABPA since 2011 and served as the secretary in several committees of SABPA. She has been awarded SABPA Achievement Award for 2012 and 2013.Dr. Ma earned her MS in Genetics from Nankai University and received her Ph.D. degree in Biomedical Sciences from University of Edinburgh, UK in 2011. [Back to top]

Back to Event Page


[dt_sc_tab title=”Register”]

Date:  June 21th, 2014, 8:00am – 4:45pm

Location: Hilton, San Diego/Del Mar

Registration: https://www.123signup.com/register?id=dhdhz

$30 for online registration before midnight of June 5, $50 for onsite registration, students and postdocs $10 off (The fees include parking at the hotel, program brochure, continental breakfast, coffee break, and lunch). Online registration closes on June 18th.

Organizer: Sino-American Biomedical & Pharmaceutical Professionals Association (SABPA)

Co-organizer: BayHelix, SDCAA (San Diego Chinese American Association), ACS-San Diego, UCSD

Sino-American Biotechnology and Pharmaceutical Professionals Association (SABPA) is a local non-profit professional organization (https://archive.sabpa.org). At this year’s San Diego Bio-Pharma Conference, we bring together top-notched speakers to discuss recent breakthroughs in life science and latest industry trends on a global scale. We are also putting together a very rare and exciting drug discovery panel representing elite local companies with drugs that have recently gained FDA approvals to showcase San Diego’s drug discovery success stories. The program is guaranteed to generate sizzling discussion and stimulate new ideas with renewed enthusiasm of investing in San Diego biotech.


[dt_sc_tab title=”Direction”]

 Hilton San Diego/Del Mar

15575 Jimmy Durante Blvd

Del Mar, CA 92014



[dt_sc_tab title=”Sponsor”]


[dt_sc_tab title=”Contact”]

Mail SABPA, San Diego
PO Box. 927631,
San Diego, CA 92192-7631
(include sponsor payment)

Sponsorship Information Please click herefor the details.
Membership member@sabpa.org
Information info4@sabpa.org
Webmaster webmaster@sabpa.org


[dt_sc_tab title=”Photos”]
2014 BioPharma Conference photo report

[dt_sc_tab title=”Previous”]

2013 Biopharma Eventhttps://archive.sabpa.org/2013/06/paving-the-path-to-success-the-12th-annual-symposium-on-biopharmaceuticals/

Events before 2013, please visit www.sdbiopharma.org